BCAL Diagnostics Limited (AU:BDX)
ASX:BDX
Want to see AU:BDX full AI Analyst Report?
BDX Stock Chart & Stats
AU$0.10
>-AU$0.01(-2.06%)
At close: 4:00 PM EST
AU$0.10
>-AU$0.01(-2.06%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.16
Previous CloseN/A
Volume98.04K
Average Volume (3M)421.90K
Market Cap
AU$31.34M
Enterprise ValueAU$34.36M
Total Cash (Recent Filing)AU$3.33M
Total Debt (Recent Filing)AU$3.78M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding368,683,300
10 Day Avg. Volume534,308
30 Day Avg. Volume421,904
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)3.64
Price to Sales (P/S)1047.06
P/FCF Ratio-3.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthThe company's moderate leverage (debt-to-equity ~0.38) and roughly 63% equity ratio provide a durable financial cushion. This capital structure reduces near-term solvency pressure and preserves flexibility to fund R&D, regulatory processes, or targeted operations over the next several months without immediate distress financing.
Focused Diagnostic Business ModelBDX's concentrated focus on blood-based breast cancer diagnostics and related IP targets a structural healthcare need with high clinical value. Specialized assays and proprietary IP can create barriers to entry and enable recurring lab-service or licensing revenue if clinically validated and commercialized, supporting medium-term strategic optionality.
Free Cash Flow Conversion Relative To Net LossDespite negative operating cash flow, a free cash flow to net income ratio above 1 suggests some cash conversion versus accounting losses. That limited cash-generation characteristic can modestly extend runway for development activities and reduce immediate liquidity stress while management pursues validation or partnerships.
Bears Say
Severe Revenue DeclineA near-total revenue collapse severely undermines scale economics and the company's ability to fund clinical validation, regulatory submissions, and commercialization effort. Sustained revenue restoration is essential to achieve operating leverage; without it the business faces structural viability and partner-negotiation challenges over the medium term.
Deep Losses And Negative ReturnsExtremely negative margins and ROE indicate persistent destruction of shareholder capital and an inability to convert operations into profits. This fundamental unprofitability escalates dependence on external financing, risks dilution, and impairs credibility with strategic partners or payers needed for long-term commercial traction.
Weak Cash Generation TrendNegative operating and free cash flows, together with declining FCF growth, constrain the company's runway and capacity to fund R&D or scale lab operations organically. Ongoing cash burn raises execution risk, increases the likelihood of dilutive raises, and limits ability to pursue regulatory or commercialization milestones in the coming months.
BCAL Diagnostics Limited News
BDX FAQ
What was BCAL Diagnostics Limited’s price range in the past 12 months?
BCAL Diagnostics Limited lowest share price was AU$0.05 and its highest was AU$0.15 in the past 12 months.
What is BCAL Diagnostics Limited’s market cap?
BCAL Diagnostics Limited’s market cap is AU$31.34M.
When is BCAL Diagnostics Limited’s upcoming earnings report date?
BCAL Diagnostics Limited’s upcoming earnings report date is Sep 01, 2026 which is in 132 days.
How were BCAL Diagnostics Limited’s earnings last quarter?
BCAL Diagnostics Limited released its earnings results on Feb 17, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.
Is BCAL Diagnostics Limited overvalued?
According to Wall Street analysts BCAL Diagnostics Limited’s price is currently Overvalued.
Does BCAL Diagnostics Limited pay dividends?
BCAL Diagnostics Limited does not currently pay dividends.
What is BCAL Diagnostics Limited’s EPS estimate?
BCAL Diagnostics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BCAL Diagnostics Limited have?
BCAL Diagnostics Limited has 368,683,300 shares outstanding.
What happened to BCAL Diagnostics Limited’s price movement after its last earnings report?
BCAL Diagnostics Limited reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.348%.
Which hedge fund is a major shareholder of BCAL Diagnostics Limited?
Currently, no hedge funds are holding shares in AU:BDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BCAL Diagnostics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
AU:BDX Sentiment 67%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth AU$83.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.16%
12-Months-Change
Fundamentals
Return on Equity
-164.22%
Trailing 12-Months
Asset Growth
-37.01%
Trailing 12-Months
Company Description
BCAL Diagnostics Limited
BCAL Diagnostics Limited, a biotechnology company, engages in developing a non-invasive laboratory blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vesicles from a patient's plasma or blood sample to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
Technical Analysis
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
―
Imagion Biosystems Ltd.
―
Inoviq Ltd
―
Options Prices
Currently, No data available
---